| Excerpt | Reference |
|---|
| "Patients with untreated B-cell chronic lymphocytic leukemia have a high rate of complete remission when given the halogenated nucleoside analogue fludarabine." | ( Elmhorn-Rosenborg, A; Juliusson, G; Liliemark, J, 1992) |
| "Not all patients with B-cell chronic lymphocytic leukemia require therapy." | ( Phyliky, RL; Tefferi, A, 1992) |
| "Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-II) disease were treated with fludarabine as a single agent." | ( Childs, CC; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; McCredie, KB; O'Brien, S; Schachner, J; Talpaz, M, 1991) |
| "In 1980, the French Cooperative Group on Chronic Lymphocytic Leukemia started a randomized clinical trial in which 612 good prognosis patients (stage A) received either no treatment (309 patients) or an indefinite course of chlorambucil at the daily dose of 0." | ( , 1990) |
| "Since lymphocytes of patients with chronic lymphocytic leukemia respond to treatment with glucocorticosteroids and are cortisol sensitive, we attempted to see whether their capability to catabolize cortisol differs from that of normal lymphocytes." | ( Amato, DJ; Bruser, B; Curtis, JE; Klein, A; Lishner, M; Malkin, A, 1990) |
| "About 19-26% of patients with chronic lymphocytic leukemia (CLL) have intractable disease resistant to chemotherapy, have a relatively short median survival time and are responsive to splenectomy." | ( Schrek, R, 1990) |
| "A cell line derived from a B-type chronic lymphocytic leukemia, Corinna II, was found to down-regulate its steady-state level of IgM mRNA after treatment with phorbol 12-myristate 13-acetate while the proliferative capacity of the cell line was unaffected." | ( Leanderson, T; Mårtensson, IL; Nilsson, K, 1989) |
| "A case of chronic lymphocytic leukemia (CLL) treated with chlorambucil, followed by the development of an acute monoblastic leukemia, is described." | ( Assens, C; Breton, A; Charlier, D; Donadio, D; Emberger, JM; Lavabre-Bertrand, T; Murgue, B; Poncelet, P; Taib, J; Vendrell, JP, 1989) |
| "Simultaneous presentation of chronic lymphocytic leukemia and polycythemia vera is reported in a previously untreated patient." | ( Botelho de Sousa, A; Gouveia, J, 1989) |
| "Many patients with chronic lymphocytic leukemia (CLL) achieve remission after treatment with fludarabine chemotherapy." | ( Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE, 1995) |
| "Twenty four patients with refractory chronic lymphocytic leukemia (CLL) and advanced low grade lymphoma (LGL) were treated with Fludarabine given at a dose of 25 mg/m2, intravenously daily for 5 days, every 28 days." | ( Cass, Y; Dann, EJ; Gillis, S; Polliack, A; Rochlemer, RR, 1994) |
| "Ninety patients with advanced chronic lymphocytic leukemia were treated with 2-CdA administered either as a 0." | ( Piro, LD; Saven, A, 1993) |
| "B-cell chronic lymphocytic leukemia (CLL) initially responds well to treatment with alkylating agents, but subsequently resistance may develop." | ( Juliusson, G; Liliemark, J, 1994) |
| "Fifteen patients with chronic lymphocytic leukemia (CLL) were treated in a phase I-II study of chlorambucil with an escalating dose of fludarabine." | ( Berman, E; Kempin, S; Spiess, T; Weiss, M, 1994) |
| "Patients with lymphoma and chronic lymphocytic leukemia (CLL) treated at the M." | ( Cabanillas, F; Gandhi, V; Gregoire, V; Keating, MJ; McLaughlin, P; O'Brien, S; Plunkett, W; Robertson, LE; Yang, L, 1994) |
| "The major complication during therapy of chronic lymphocytic leukemia (CLL) with the purine nucleotide analogue fludarabine is infection, which is also the main cause of morbidity and mortality in the disease." | ( Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Kemena, A; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, L, 1993) |
| "Twenty-seven patients with B-cell chronic lymphocytic leukemia (CLL) or a related lymphoid malignancy were treated with high-dose cytosine arabinoside (ara-C) at a dosage of 3 gm/m2 administered over 2 hours every 12 hours at one to four doses per course, which were repeated at 4-week intervals." | ( Estey, E; Hagemeister, FB; Hall, R; Kantarjian, HM; Keating, MJ; McLaughlin, P; Plunkett, W; Robertson, LE, 1993) |
| "Two hundred sixty-four patients with chronic lymphocytic leukemia were treated with fludarabine 30 mg/m2 intravenously for 30 minutes each day for 5 days and with prednisone 30 mg/m2 orally each day for 5 days." | ( Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Lerner, S; O'Brien, S; Robertson, LE; Smith, T, 1993) |
| "In this patient with chronic lymphocytic leukemia, carbamazepine therapy had a significant and reproducible lymphopenic effect that was readily reversible upon discontinuation of the drug." | ( Chapron, DJ; Silverman, DA, 1995) |
| "Twenty eligible patients with NHL and chronic lymphatic leukemia (CLL), resistant to or relapsed after previous protocols of polychemotherapy were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle." | ( Bairey, O; Blickstein, D; Hadar, H; Lahav, M; Prokocimer, M; Shaklai, M; Shaklai, S; Sulkes, J, 1996) |
| "The expression of CD38 by B cells chronic lymphocytic leukemia (B-CLL) was studied in 20 untreated patients." | ( Cosulich, E; Dono, M; Ferrarini, M; Isnardi, L; Malavasi, F; Massara, R; Megna, M; Zupo, S, 1996) |
| "Thirty patients with B-chronic lymphocytic leukemia, aged 45-82 years, were treated with fludarabine." | ( Gjedde, SB; Hansen, MM, 1996) |
| "The treatment of chronic lymphocytic leukemia includes the use of alkylating agents, steroids, and more recently nucleoside analogues." | ( Gartenhaus, RB; Hoffman, M; Janson, D; Rai, KR; Wang, P, 1996) |
| "We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia (AIHA) after fludarabine treatment." | ( Bayle, C; Cartron, J; Lambert, T; Rudent, A; Tchernia, G; Tertian, G, 1996) |
| "New drugs for the treatment of chronic lymphocytic leukemia are purine-analogs." | ( Adam, Z; Hejlová, N; Vorlícek, J, 1996) |
| "Patients with advanced, refractory chronic lymphocytic leukemia (CLL) have an high morbidity and mortality from infections following chemotherapy-induced myelosuppression." | ( Itälä, M; Remes, K; Vanhatalo, S, 1997) |
| "53-year-old man with chronic lymphocytic leukemia resistant to alkylating agent containing regimens, was treated with fludarabine phosphate." | ( Soda, R; Tada, A; Takahashi, K; Takeuchi, M, 1997) |
| "Cells from 31 patients with chronic lymphocytic leukemia (CLL) were treated in vitro with 2-chlorodeoxyadenosine (CdA), arabinosyl-2-fluoroadenine (F-ara-A), or chlorambucil (CLB) and drug sensitivity measured using the MTT assay." | ( Begleiter, A; Daeninck, P; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L; Williams, G, 1997) |
| "We also treated 14 patients with chronic lymphocytic leukemia with cladribine and obtained an overall response rate of 43%; this required several courses of monthly treatment." | ( Rai, KR, 1998) |
| "402 patients with chronic lymphocytic leukemia not previously treated or treated with chlorambucil (with or without prednisone) who received fludarabine (30 mg/m2 of body surface area per day for 5 days) with or without prednisone at 4-week intervals." | ( Anaissie, EJ; Kantarjian, H; Keating, MJ; Kontoyiannis, DP; Lerner, S; O'Brien, S; Robertson, L, 1998) |
| "infusions in the treatment of B cell chronic lymphocytic leukemia (B-CLL) in patients 55 years old and younger." | ( Błasińska-Morawiec, M; Błoński, JZ; Robak, T; Skotnicki, AB; Urbańska-Ryś, H, 1999) |
| "We report chronic lymphocytic leukemia-associated PNP in a patient who presented with extensive and debilitating painful oral ulcerations and received ablative therapy." | ( Anhalt, GJ; Brodsky, RA; Grever, MR; Jones, RJ; Nousari, HC, 1999) |
| "Patients with chronic lymphocytic leukemia (CLL) frequently respond to initial treatment, but then become resistant to chemotherapy." | ( Burmester, JK; Friedenberg, WR; Phan, SM; Salzman, SA, 1999) |
| "Fludarabine has widely been studied in chronic lymphocytic leukemia (CLL), with impressive remission rates in refractory, relapsed or untreated disease." | ( Demeter, J; Lehoczky, D; Varga, F, 1999) |
| "Patients with chronic lymphocytic leukemia (CLL) who fail fludarabine (Fluda) therapy have a poor response to subsequent salvage regimens and a poor prognosis." | ( Gandhi, V; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Plunkett, W; Robertson, LE; Santini, V; Seymour, JF, 1999) |
| "B cell chronic lymphocytic leukemia (B-CLL) cannot be cured with conventional chemotherapy." | ( Bauer, O; Golfier, S; Klein, A; Miera, O; Schriever, F, 2000) |
| "A case of PML in a chronic lymphocytic leukemia (CLL) patient treated with fludarabine is reported, representing the second such instance in which the diagnosis of the neurological disorder was established by brain biopsy." | ( Cervantes, F; Cervera, A; Cid, J; Ferrer, I; Montserrat, E; Muñoz, E; Revilla, M, 2000) |
| "When used as the initial treatment for chronic lymphocytic leukemia, fludarabine yields higher response rates and a longer duration of remission and progression-free survival than chlorambucil." | ( Appelbaum, FR; Cheson, BD; Elias, L; Hines, J; Kolitz, J; Larson, RA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L; Threatte, GA, 2000) |
| "Fludarabine is used to treat chronic lymphocytic leukemia." | ( Acquaah-Mensah, GK; Biswal, SS; Datta, K; Kehrer, JP, 2000) |
| "B-cell chronic lymphocytic leukemia (CLL) is the most common type of leukemia diagnosed in the Western Hemisphere and remains incurable with currently available therapy." | ( Byrd, JC; Flinn, IW; Grever, MR; Shinn, CA; Waselenko, JK, 2001) |
| "In patients with chronic lymphocytic leukemia (CLL), TK levels may provide prognostic information independent of stage and other prognostic factors, but it is still unclear whether they can be used to predict the response to treatment and length of survival." | ( Cacciola, E; Di Raimondo, F; Giustolisi, R; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S, 2001) |
| "Patients with chronic lymphocytic leukemia (CLL) treated with adenovirus (Ad)-CD154 (CD40L) gene therapy experience reductions in leukemia cell counts and lymph node size associated with induction of the death receptor Fas (CD95)." | ( Chu, P; Deforce, D; Kim, Y; Kipps, TJ; Kitada, S; Pedersen, IM; Reed, JC, 2002) |
| "Patients with chronic lymphocytic leukemia or low-grade non-Hodgkin's lymphoma were randomly assigned to two groups, both of which received two cycles of treatment with 90 mg of oral fludarabine phosphate administered when either fed or fasted." | ( Culligan, D; Cunningham, D; Gieschen, H; Johnson, S; Klein, M; Orchard, JA; Oscier, D; Parker, A, 2001) |
| "Treatments for fludarabine-refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are limited." | ( Byrd, JC; Flynn, JM; Howard, RS; Perkins, JG, 2002) |
| "Two patients, one with B-cell chronic lymphocytic leukemia (CLL) and one with hairy-cell leukemia (HCL), were treated with immunosuppressive chemotherapy." | ( Clausen, NT; Hansen, PB; Larsen, CR, 2002) |
| "A 65-year-old man with chronic lymphocytic leukemia (CLL) diagnosed 11 years ago and treated with standard dose of fludarabine developed a rapidly fatal progressive neurological syndrome." | ( Castells, G; Escoda, L; Marés, R; Richart, C; Saumoy, M; Ugarriza, A, 2002) |
| "We describe a patient with chronic lymphatic leukemia who developed disseminated cutaneous MAC lesions refractory to conventional antimycrobial therapy." | ( Binstock, P; Keating, M; Kontoyiannis, DP; Nannini, EC; Samonis, G, 2002) |
| "Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) patients often develop anemia due to the disease process and effects from disease therapy." | ( Blade, J; Dammacco, F; Degos, L; Itri, L; Kyle, R; Liso, V; Littlewood, TJ; Ludwig, H; Mandelli, F; Meloni, G; Molica, S; Osterborg, A; Pangalis, GA; Rai, K; San Miguel, J; Schmitt, B; Voliotis, D, 2002) |
| "Patients with chronic lymphocytic leukemia (CLL) may have disease transformation to non-Hodgkin's lymphoma or prolymphocytic leukemia; however, development of therapy-related acute myeloid leukemia (t-AML) is unusual." | ( Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L, 2002) |
| "We report a patient treated for small lymphocytic lymphoma/leukemia with cerebral venous and sinus thrombosis (CVST) after lumbar puncture with intrathecal administration of methotrexate (MTX)." | ( Bienfait, HP; de Bruin, HG; Gijtenbeek, JM; Pillay, M; van den Bent, MJ; Voogt, PJ, 2002) |
| "A significant number of chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma and Waldenström's macroglobulinemia patients, treated with fludarabine phosphate (fludarabine), are elderly with diminished renal function." | ( Budman, DR; Cascella, P; D'Amico, P; Eisenberg, P; Etcubanas, E; Ferrer, JM; Hinderling, PH; Lichtman, SM; Melikian, A; Musgrave, K; O'Mara, V; Williams, GJ; Zervos, G, 2002) |
| "We successfully treated a patient with chronic lymphocytic leukemia (CLL) associated with a nephrotic syndrome." | ( Horie, T; Horikoshi, A; Hosokawa, Y; Sawada, S; Takei, K, 2002) |
| "Therapy of B-cell chronic lymphocytic leukemia (CLL) is currently palliative, emphasizing the need for identification of new therapies for this disease." | ( Byrd, JC; Drabick, JJ; Grever, MR; Kitner, JB; Lucas, DM; Mone, AP, 2003) |
| "B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of growth arrested clonal B lymphocytes that undergo apoptosis when treated with fludarabine." | ( Ajchenbaum-Cymbalista, F; DeCaprio, JA; Delmer, A; Sanhes, L; Tang, R, 2003) |
| "The most common treatment of chronic lymphocytic leukemia (CLL) is the alkylating agent chlorambucil (CLB), with or without prednisone." | ( Amiel, A; Biton, I; Fejgin, MD; Gaber, E; Lishner, M; Yukla, M, 2003) |
| "Ongoing studies in B-cell chronic lymphocytic leukemia are evaluating autologous peripheral blood stem cell (PBSC) transplantation in first remission following fludarabine therapy." | ( Azar, N; Bastit, D; Belhadj, K; Cazin, B; Delmer, A; Diviné, M; Feugier, P; Grosbois, B; Leprètre, S; Maloisel, F; Maloum, K; Manhès, G; Michallet, M; Tournilhac, O; Travade, P; Villard, F; Villemagne, B, 2004) |
| "The standard treatments for chronic lymphocytic leukemia (CLL) include the alkylating agent chlorambucil (CLB) and the nucleoside analog fludarabine (F-ara-AMP, Flu)." | ( Begleiter, A; Gibson, SB; Hu, X; Johnston, JB; Kabore, AF; Kropp, DM; Kuschak, B; Paul, JT; Strutinsky, J, 2003) |
| "Treatment options for patients with chronic lymphocytic leukemia have changed over the past two decades." | ( Ferrajoli, A; O'Brien, SM, 2004) |
| "Patients with chronic lymphocytic leukemia (CLL) are sometimes resistant to treatment or relapse soon after the administration of the currently available frontline therapy including chlorambucil-prednisolone CHOP and fludarabine." | ( Bourantas, KL; Chaidos, A; Christou, L; Kapsali, HD; Tsiara, SN, 2004) |
| "We analyzed 38 untreated patients with chronic lymphocytic leukemia of B-cell type (B-CLL): 24 low-, 8 intermediate-, and 6 high-risk stage." | ( Caligaris-Cappio, F; Catellani, S; Clavio, M; Ghia, P; Gobbi, M; Miglino, M; Poggi, A; Steinle, A; Stella, S; Venturino, C; Zocchi, MR, 2004) |
| "Clinical treatment of B-cell chronic lymphocytic leukemia (B-CLL) is limited by the progressive drug resistance and nonselectivity of most drugs towards malignant cells." | ( Escobar-Díaz, E; García-Marco, JA; Garcia-Pardo, A; Giralt, E; Hernández del Cerro, M; López-Martín, EM; Montaner, B; Pérez-Tomás, R; Puig-Kroger, A; Soto-Cerrato, V, 2005) |
| "Patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) have a short life expectancy." | ( Agura, E; Al-Ali, H; Blume, KG; Bredeson, C; Bruno, B; Chauncey, TR; Hegenbart, U; Langston, A; Leis, J; Loken, MR; Maloney, DG; Maris, MB; McSweeney, P; Pulsipher, M; Radich, JP; Sandmaier, BM; Sorror, ML; Storb, R; Storer, BE; Stuart, MJ, 2005) |
| "Patients with chronic lymphocytic leukemia (CLL) treated with adenovirus CD154 (Ad-CD154, CD40 ligand [CD40L]) gene therapy experienced rapid reductions in leukemia cell counts and lymph node size associated with the induced expression of Fas (CD95)." | ( Dicker, F; Houghten, R; Kater, AP; Kipps, TJ; Mangiola, M; Nefzi, A; Ostresh, J; Pinilla, C; Reed, JC; Welsh, K, 2005) |
| "We assessed 73 patients with B-cell chronic lymphocytic leukemia (CLL) and 42 healthy controls and demonstrated significantly increased frequencies of cytotoxic T lymphocyte-associated protein 4 (CTLA4+)-, Forkhead box P3 (FOXP3+)-, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR+)-, CD62L+-, transforming growth factor beta1 (TGF-beta1+)-, interleukin 10 (IL-10+)-Treg cells in patients with CLL, with highest frequencies in untreated or progressing patients presenting with extended disease." | ( Beyer, M; Darabi, K; Debey, S; Endl, E; Hallek, M; Jensen, M; Knolle, PA; Kochanek, M; Popov, A; Schultze, JL; Thomas, RK; von Bergwelt-Baildon, M, 2005) |
| "In the DNA of untreated patients with chronic lymphocytic leukemia (CLL), uracil and high levels of etheno-adenine were found, which can be explained by antioxidant enzyme alterations and oxidative stress in the CLL lymphocytes." | ( Altenbach, HJ; Gäb, S; Oscier, D; Podeschwa, MA; Schellenträger, M; Schmitz, OJ; Schumann, CA; Vom Brocke, J; Wirtz, M, 2005) |
| "Flavopiridol is active against chronic lymphocytic leukemia (CLL) cells in vitro and in the treatment of advanced stage disease, but the mechanisms of these actions remain unclear." | ( Chen, R; Gandhi, V; Keating, MJ; Plunkett, W, 2005) |
| "We present four patients with chronic lymphocytic leukemia treated with fludarabine, who developed aggressive skin cancer after years of quiescence, a short time after institution of treatment." | ( Hirschman, R; Mastan, A; Ng, R; Rashid, K; Sager, D, 2005) |
| "We report a patient with chronic lymphocytic leukemia (CLL) who developed idiopathic thrombocytopenic purpura (ITP) and myasthenia gravis (MG) after fludarabine therapy." | ( Baba, Y; Fujimaki, K; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Takabayashi, M; Takasaki, H; Yamaji, S, 2005) |
| "Patients with chronic lymphocytic leukemia (CLL) can relapse even after aggressive therapy and autografts." | ( Cetkovský, P; Dvorák, M; Marková, J; Pajer, P; Peková, S; Schwarz, J, 2005) |
| "A 70-year-old man with B-cell chronic lymphocytic leukemia (CLL) received single-agent treatment with the purine analogue fludarabine, which led to complete remission." | ( Kwong, YL; Lam, CC; Ma, ES, 2005) |
| "We report the case of a patient with chronic lymphatic leukemia (CLL) who experienced tumor lysis syndrome (TLS) with acute renal failure after fludarabine/cyclophosphamide chemotherapy and after bendamustine treatment." | ( Adam, K; Bergmann, J; Buchheidt, D; Hehlmann, R; Hummel, M; Reiter, S, 2005) |
| "We studied 40 patients with B-cell chronic lymphocytic leukemia (B-CLL) at diagnosis, before treatment and four weeks after therapy." | ( Bukin, M; Jabłońska, E; Kiersnowska-Rogowska, B; Parfieńczyk, A; Puzewska, W; Rogowski, F, 2005) |
| "All five patients with chronic lymphocytic leukemia (CLL) experienced chemotherapy-induced HBV reactivation regardless of the chemotherapy regimen." | ( Acar, K; Aki, Z; Bozdayi, G; Haznedar, R; Sucak, GT; Yağci, M, 2006) |
| "Although chronic lymphocytic leukemia (CLL) remains an incurable disease with standard chemotherapy, the appropriate role and timing of transplantation are unclear." | ( Alyea, EP; Antin, JH; Brown, JR; Cutler, C; Fisher, DC; Gribben, JG; Ho, V; Kim, HT; Lee, SJ; Li, S; Milford, EL; Ritz, J; Soiffer, RJ; Stephans, K, 2006) |
| "Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have profound immune defects and limited treatment options." | ( Bernstein, ZP; Byrne, C; Chanan-Khan, A; Chrystal, C; Czuczman, MS; Goodrich, DW; Hernandez-Ilizaliturri, F; Lawrence, D; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Porter, CW; Spaner, D; Starostik, P; Takeshita, K; Wallace, P, 2006) |
| "Patients with multiple myeloma or chronic lymphocytic leukemia who were treated on thalidomide based-combination therapies were treated on low-dose warfarin (1 or 2 mg) continuously through the duration of their therapy." | ( Chanan-Khan, A; Depaolo, D; Dimicelli, L; Doran, V; Landrigan, B; Marshal, P; Miller, KC; Padmanabhan, S; Yu, J, 2006) |
| "Progressive B-cell chronic lymphocytic leukemia (B-CLL) is often complicated by autoimmune hemolytic anemia (AIHA), which in some cases may be refractory to conventional therapy such as corticosteroids, rituximab and splenectomy." | ( Celsing, F; Hansson, L; Karlsson, C; Lundin, J, 2007) |
| "Patients with B-cell chronic lymphocytic leukemia (B-CLL) often demonstrate variable responses to similar treatments." | ( Bakke, AC; Braziel, RM; Fan, G; Gatter, KM; Huang, JZ; Leis, JF; Maziarz, RT; Zhong, Y, 2007) |
| "In a patient with chronic lymphatic leukemia (CLL) infiltrates of the skin of the whole scalp, conventional external-beam radiotherapy with electrons or photons was not able to treat the target sufficiently." | ( Heinicke, F; Hildebrandt, G; Liebmann, A; Pohlmann, S, 2007) |
| "We report on a patient with relapsed chronic lymphocytic leukemia (CLL) treated with the novel mTOR inhibitor RAD001 within a phase II clinical trial." | ( Decker, T; Fend, F; Götze, KS; Hoffmann, D; Peschel, C; Schätzl, HM, 2007) |
| "Most cats with lymphocytic lymphoma responded to treatment with prednisone and chlorambucil, and most factors evaluated were not associated with outcome." | ( Erb, HN; Goldstein, RE; Kiselow, MA; McDonough, SP; Rassnick, KM; Simpson, KW; Weinkle, TK, 2008) |
| "Although B-cell chronic lymphocytic leukemia (CLL) is treatable, it remains an incurable disease and most patients inevitably suffer relapse." | ( Decker, T; Goetze, K; Oelsner, M; Peschel, C; Ringshausen, I; Sandherr, M, 2009) |
| "B-cell chronic lymphocytic leukemia (CLL), the most common leukemia in older adults, remains largely incurable and novel treatments are urgently required." | ( Birtwistle, J; Bunce, CM; Davies, NJ; Delgado, J; Drayson, MT; Hayden, RE; Khanim, FL; Pearce, C; Pratt, G; Sant, T, 2009) |
| "SNS-032 effectively killed chronic lymphocytic leukemia cells in vitro regardless of prognostic indicators and treatment history." | ( Chen, R; Chubb, S; Fox, JA; Gandhi, V; Hawtin, RE; Keating, MJ; Plunkett, W; Wierda, WG, 2009) |
| "We treated patients with chronic lymphocytic leukemia (CLL) with a combined thalidomide/fludarabine regimen and monitored cellular and molecular changes induced by thalidomide in vivo before fludarabine treatment." | ( Bojarska-Junak, A; Bullinger, L; Dmoszynska, A; Döhner, H; Giannopoulos, K; Kowal, M; Rolinski, J; Stilgenbauer, S; Wasik-Szczepanek, E, 2009) |
| "Patients with purine analogue-refractory chronic lymphocytic leukemia (CLL) have short survival and limited treatment options." | ( Ferrajoli, A; Motta, M; Wierda, WG, 2009) |
| "We present a patient with chronic lymphocytic leukemia who died from Pneumocystis pneumonia (PCP) despite appropriate anti-Pneumocystis therapy." | ( Kovacs, JA; Masur, H, 2009) |
| "Advances in the treatment of chronic lymphocytic leukemia (CLL) have improved initial overall response (OR) rates, complete response (CR) rates and progression free survival (PFS)." | ( Lin, TS; Maddocks, KJ, 2009) |
| "Use of this modality in patients with chronic lymphocytic leukemia (CLL) has been hampered by the extensive marrow involvement seen in patients with CLL, which would produce a high risk for marrow aplasia after treatment with RIT." | ( Ferrajoli, A; Jain, N; Keating, M; Lerner, S; O'Brien, S; Wierda, W; Wong, F, 2009) |
| "A patient with chronic lymphocytic leukemia received [6,6-(2)H(2)]-glucose (1 g/kg) orally in aliquots administered every 30 min for a period of 10 h." | ( Defoiche, J; Hegedus, A; Lagneaux, L; Macallan, DC; Pettengell, R; Willems, L; Zhang, Y, 2009) |
| "Patients with relapsed chronic lymphocytic leukemia were treated with lenalidomide 20 mg (n=10) or 10 mg (n=8) daily for 3 weeks on a 6-week cycle." | ( Aue, G; Boss, C; Gibellini, F; Hughes, T; Keyvanfar, K; McCoy, JP; Njuguna, N; Pittaluga, S; Samsel, L; Soto, S; Tian, X; Valdez, J; Vire, B; Wiestner, A; Wilson, WH, 2009) |
| "Patients with chronic lymphocytic leukemia (CLL) with high-risk cytogenetic features such as del(17p13) have limited treatment options and decreased overall survival." | ( Byrd, JC; Christian, BA; Grever, MR; Lin, TS, 2009) |
| "Progress in our understanding of chronic lymphocytic leukemia and its treatment has resulted in a more tailored approach to patient management, with different therapeutic regimens for different patient populations." | ( Foon, KA; Hallek, MJ, 2010) |
| "Patients with recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) often have chemotherapy-resistant disease, resulting in poor prognosis." | ( Call, TG; Habermann, TM; Johnston, PB; LaPlant, BR; Micallef, IN; Witzig, TE; Zent, CS, 2010) |
| "Despite advances in treatment, chronic lymphocytic leukemia (CLL) remains incurable with standard therapies." | ( Lin, TS, 2010) |
| "Patients with chronic lymphocytic leukemia (CLL) with primary resistance to fludarabine-based therapy or with progressive disease were eligible for oral forodesine (200 mg/d) for up to 24 weeks." | ( Balakrishnan, K; Bantia, S; Bickel, S; Chen, Y; Gandhi, V; Kantarjian, H; Keating, MJ; Kilpatrick, JM; O'Brien, S; Ravandi, F; Tyler, BF; Verma, D, 2010) |
| "Thirty B-cell chronic lymphocytic leukemia patients were treated with fludarabine-cyclophosphamide-rituximab (FCR) and immune cell counts (natural killer (NK) cells, CD4, CD8, Tgammadelta and monocytes) were monitored from the end of treatment (EOT) up to 36 months (M36)." | ( Blanc, A; Corre, J; Fournié, JJ; Gross, E; Kühlein, E; Laurent, G; Quillet-Mary, A; Ysebaert, L, 2010) |
| "B-cell chronic lymphocytic leukemia (B-CLL) therapy remains unsatisfactory due to repeated resurgences of the chemoresistant disease." | ( Brassac, M; Fournié, JJ; Gross, E; Kheirallah, S; L'Faqihi-Olive, FE; Laurent, G; Quillet-Mary, A; Struski, S; Ysebaert, L, 2010) |
| "The sensitivity of chronic lymphocytic leukemia (CLL) cells to current treatments, both in vitro and in vivo, relies on their ability to activate apoptotic death." | ( Brugat, T; Chevillard, S; Delic, J; Gault, N; Kruhoffer, M; Marteau, JB; Merle-Beral, H; Nguyen-Khac, F; Orntoft, TF; Rigaud, O; Vallat, L, 2010) |
| "Treatment outcome of chronic lymphocytic leukemia (CLL) has considerably improved since the introduction of fludarabine (F) as part of the standard therapy." | ( Schnaiter, A; Stilgenbauer, S, 2010) |
| "Although modern treatment options for B-chronic lymphocytic leukemia (CLL) produce high response rates, virtually all patients relapse, presumably due to the persistence of minimal residual disease (MRD)." | ( Kay, NE; O'Brien, S, 2011) |
| "Since the progression of chronic lymphocytic leukemia(CLL)is long and requires lengthy primary disease management, the risk of double primary cancers and secondary cancer due to treatment has become an issue in western countries with a high incidence of CLL." | ( Hattori, H; Karasuno, T; Kotake, T; Kuwayama, M, 2011) |
| "In patients with chronic lymphocytic leukemia (CLL), treatment with lenalidomide induces a unique, previously uncharacterized, immune response called tumor flare reaction (TFR)." | ( Chanan-Khan, A; Czuczman, MS; Hernandez-Illatazurri, F; Lawrence, D; Lee, K; Miller, A; Miller, KC; Padmanabhan, S; Wallace, PK; Zeldis, JB, 2011) |
| "The increase of fludarabine-resistant chronic lymphocytic leukemia (CLL) presents a new treatment challenge." | ( Jäger, U; Janssens, A; Leblond, V; Lepretre, S; Nikitin, E; Robak, T; Wendtner, CM, 2012) |
| "Clinically, CD69 positive chronic lymphocytic leukemias received chemotherapy more frequently (74%; P<0." | ( Amadori, S; Biagi, A; Bomben, R; Bruno, A; Buccisano, F; Bulian, P; Coletta, AM; Dal Bo, M; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Gattei, V; Luciano, F; Maurillo, L; Neri, B; Rossi, FM; Simotti, C; Venditti, A; Zucchetto, A, 2012) |
| "Older chronic lymphocytic leukemia patients have poor outcomes with standard treatments and are underrepresented in clinical trials." | ( Blum, K; Byrd, JC; Flynn, JM; Grever, MR; Ji, J; Johnson, AJ; Jones, J; Phelps, MA; Ruppert, AS; Stephens, DM, 2012) |
| "Stroma induces treatment resistance in chronic lymphocytic leukemia (CLL), possibly because of alterations in the BCL-2 family of proteins, which are key regulators of apoptosis." | ( Brown, JR; Davids, MS; Deng, J; Lannutti, BJ; Letai, A; Wang, L; Wiestner, A; Wilson, WH; Wu, CJ, 2012) |
| "The differences in clinical course of chronic lymphocytic leukemia could have an impact on variations in a patient's response to therapy." | ( Błoński, JZ; Franiak-Pietryga, I; Góralski, P; Janus, A; Kiliańska, ZM; Maciejewski, H; Mirowski, M; Piekarski, H; Robak, P; Robak, T; Rogalińska, M, 2013) |
| "Patients with relapsed chronic lymphocytic leukemia requiring treatment after one previous systemic regimen (usually chlorambucil-based) were randomized to either receive bendamustine 100 mg/m(2) on days 1 and 2 of a 4-week cycle or standard fludarabine treatment consisting of 25 mg/m(2) on days 1 to 5 every 4 weeks." | ( Balleisen, L; Eimermacher, H; Freier, W; Heit, W; Hinke, A; Ibach, S; Knauf, W; Megdenberg, D; Niederle, N; Weiß, J, 2013) |
| "Treatment of patients with B-cell chronic lymphocytic leukemia (CLL) relapsed/refractory (R/R) to conventional treatments is particularly challenging." | ( Di Bona, E; Finotto, S; Laveder, F; Paolini, R; Pomponi, F; Rodeghiero, F; Ruggeri, M; Sartori, R; Trentin, L; Visco, C, 2013) |
| "The relationship between treatments of chronic lymphocytic leukemia (CLL) with cladribine (2-CdA) or chlorambucil and immune thrombocytopenia (IT) has not been yet determined." | ( Blonski, JZ; Calbecka, M; Ceglarek, B; Chojnowski, K; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Hellmann, A; Kloczko, J; Kostyra, A; Kowal, M; Kuliczkowski, K; Lewandowski, K; Mital, A; Nowak, W; Potoczek, S; Robak, T; Seferynska, I; Skotnicki, A; Stella-Holowiecka, B; Sulek, K; Trelinski, J; Warzocha, K; Wiater, E; Zawilska, K, 2013) |
| "The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions." | ( Blum, KA; Buggy, JJ; Burger, JA; Byrd, JC; Chang, BY; Clow, F; Coleman, M; Coutre, SE; Flinn, IW; Furman, RR; Grant, B; Hedrick, E; Heerema, NA; James, DF; Johnson, AJ; Jones, JA; O'Brien, S; Sharman, JP; Sukbuntherng, J; Wierda, WG; Zhao, W, 2013) |
| "Fludarabine successfully treats chronic lymphocytic leukemia (CLL); however, its use may lead to significant myelosuppression and other toxicities." | ( Kalaycio, M; Lukenbill, J, 2013) |
| "Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy." | ( Aiello, M; Barrientos, JC; Cheson, BD; Coiffier, B; Coutre, SE; Cramer, P; Dansey, RD; Eradat, H; Ervin, T; Flinn, I; Furman, RR; Ghia, P; Hallek, M; Hillmen, P; Jahn, TM; Johnson, DM; Kipps, TJ; Lamanna, N; Li, D; Ma, S; Miller, LL; O'Brien, SM; Pagel, JM; Pettitt, AR; Sharman, JP; Stilgenbauer, S; Zelenetz, AD, 2014) |
| "Twenty-two previously untreated chronic lymphocytic leukemia patients underwent PET/CT for disease progression." | ( Bacigalupo, A; Bongioanni, F; Bottoni, G; Bruzzi, P; Campi, C; Fiz, F; Frassoni, F; Marini, C; Massollo, M; Miglino, M; Morbelli, S; Piana, M; Piva, R; Sambuceti, G, 2014) |
| "This year new data in the treatment of chronic lymphocytic leukemia, with particular focus on high unmet need populations, such as patients ‘unfit’ for intensive chemo-immunotherapy have been presented." | ( Molica, S, 2014) |
| "Most patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based treatment." | ( Cohen, D; Dearden, CE; Follows, GA; Gribben, JG; Hillmen, P; Kennedy, DB; Milligan, D; Moreton, P; Nathwani, A; Oertel, S; Oscier, DG; Pettitt, AR; Pocock, CF; Rawstron, A; Sayala, HA; Varghese, A, 2014) |
| "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients with purine analog refractory disease or TP53 dysfunction still have limited treatment options and poor survival." | ( Baig, NA; Beum, PV; Blackwell, SE; Bowen, DA; Call, TG; Conte, MJ; Frederick, LA; LaPlant, B; Lindorfer, MA; Link, BK; Taylor, RP; Veeramani, S; Viswanatha, DS; Weiner, GJ; Witzig, TE; Wu, W; Zent, CS, 2014) |
| "An 81-year-old woman with chronic lymphocytic leukemia whose condition progressed to the acute rapidly progressing stage agreed to be exclusively treated orally with 200 mg mifepristone daily." | ( Check, D; Check, JH; Cohen, R; Sarumi, M, 2014) |
| "A severely T-cell-depleted patient with chronic lymphocytic leukemia developed CMV pneumonia and high plasma viral loads that were poorly responsive to antiviral therapy." | ( Chou, S; Ercolani, RJ; Lefterova, MI; Pinsky, BA; Sahoo, MK; Strasfeld, LM, 2014) |
| "The treatment of chronic lymphocytic leukemia (CLL) with inhibitors targeting B cell receptor signaling and other survival mechanisms holds great promise." | ( de Rooij, MF; Eldering, E; Kater, AP; Spaargaren, M, 2015) |
| "Patients with relapsed chronic lymphocytic leukemia (CLL) often achieve response with chemoimmunotherapy but have short remission durations." | ( Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lee, HJ; O'Brien, S; Qiao, W; Wierda, W, 2014) |
| "In patients with chronic lymphocytic leukemia and del (17 p), the current practice guideline recommends ibrutinib as an upfront treatment option." | ( Kim, SS; Lee, CS; Rattu, MA, 2016) |
| "Bendamustine is used in the treatment of chronic lymphocytic leukemia (CLL)." | ( Arimany-Nardi, C; Campo, E; Colomer, D; Koepsell, H; Lee-Vergés, E; Montraveta, A; Pastor-Anglada, M; Puente, XS, 2015) |
| "The treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical issue." | ( Bakesova, D; Brychtova, Y; Chovancova, J; Doubek, M; Hadrabova, M; Jelinkova, E; Karban, J; Malcikova, J; Mayer, J; Mraz, M; Obrtlikova, P; Oltova, A; Panovska, A; Plevova, K; Pospisilova, S; Sebejova, L; Smardova, J; Smolej, L; Stehlikova, O; Trbusek, M; Trizuljak, J; Volfova, P, 2015) |
| "Recent research has shown that chronic lymphocytic leukemia (CLL) B-cells display a strong tendency to differentiate into antibody-secreting cells (ASCs) and thus may be amenable to differentiation therapy." | ( Darwiche, W; Dupont, S; Ghamlouch, H; Gubler, B; Guignant, C; Hodroge, A; Marolleau, JP; Ouled-Haddou, H; Royer, B; Singh, AR; Trudel, S, 2015) |
| "Compared to untreated chronic lymphocytic leukemia patients, response to collagen showed a mild further decrement on ibrutinib, while response to adenosine diphosphate improved." | ( Cullinane, AM; Farooqui, MZ; Herman, SE; Holland, SM; Lipsky, AH; Lozier, JN; Marti, G; Martyr, S; Nghiem, K; Niemann, CU; Saba, N; Soto, S; Sun, C; Tian, X; Uzel, G; Valdez, J; Wiestner, A, 2015) |
| "Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL), and especially those with purine analogue refractory disease or TP53 deletion/mutation, had a poor prognosis prior to the introduction of therapy targeting B cell receptor signaling." | ( Bowen, DA; Call, TG; Conte, MJ; LaPlant, BR; Zent, CS, 2016) |
| "A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells." | ( Barrett, DM; Beckwith, KA; Byrd, JC; Cogdill, AP; Cook, DR; Do, P; Fraietta, JA; Gill, S; Hulitt, J; Johnson, AJ; June, CH; Kudchodkar, SB; Lacey, SF; Levine, BL; Long, M; Maddocks, K; Maus, MV; McGettigan, SE; Melenhorst, JJ; Muthusamy, N; Patel, PR; Porter, DL; Ruella, M; Woyach, JA; Xu, J; Zhang, C; Zheng, Z, 2016) |
| "The cost-effectiveness of first-line chronic lymphocytic leukemia treatments was assessed among patients unsuitable for full doses of fludarabine." | ( Becker, U; Hautala, A; Kyttälä, M; Martikainen, J; Poikonen, E; Soini, E, 2016) |
| "A 70-year-old white man with stage C chronic lymphocytic leukemia who was being successfully treated with ibrutinib and rituximab developed bilateral, purpuric, painful cutaneous nodules." | ( Magro, CM; Mulvey, JJ; Nuovo, GJ, 2016) |
| "B-cell chronic lymphocytic leukemia (CLL) remains an incurable disease, and despite the improvement achieved by therapeutic regimes developed over the last years still a subset of patients face a rather poor prognosis and will eventually relapse and become refractory to therapy." | ( Castejon, R; Losada-Fernandez, I; Martinez, A; Morado, M; Perez-Aciego, P; Perez-Chacon, G; Rebolleda, N; Rosado, S; Vallejo-Cremades, MT; Vargas-Nuñez, JA, 2016) |
| "Patients with chronic lymphocytic leukemia (CLL) who receive chemoimmunotherapy and do not achieve complete remission experience significantly shortened progression-free interval (PFS)." | ( Andritsos, LA; Awan, FT; Byrd, JC; Grever, MR; Johnson, A; Jones, JA; Maddocks, K; Poi, M, 2016) |
| "Treatment recommendations in chronic lymphocytic leukemia (CLL) are based upon selected, otherwise healthy study populations mostly under 72 years of age." | ( Günther, G; Kersting, M; Kleeberg, UR; Linde, H; Tessen, HW, 2016) |
| "Treatment options for chronic lymphocytic leukemia, the most common leukemia in the United States, have expanded rapidly in recent years." | ( Marini, BL; Perissinotti, AJ; Samanas, L, 2017) |
| "This study evaluates outcomes in chronic lymphocytic leukemia (CLL) based on first-line therapy in a large consecutive population-based cohort of 669 patients with fluorescence in-situ hybridization (FISH) data in British Columbia, Canada during the period when chemoimmunotherapy was standard first-line treatment." | ( Bruyere, H; Gerrie, AS; Gillan, TL; Hrynchak, M; Huang, SJ; Jayasundara, KS; Karsan, A; Lee, LJ; Ramadan, KM; Smith, AC; Toze, CL, 2017) |
| "The introduction of miR profiling of chronic lymphocytic leukemia (CLL) patients with different cytogenetic profiles and responses to therapy has allowed incorporation of important miR-mRNA interactions into the understanding of disease biology." | ( Andritsos, LA; Byrd, JC; Fabian, C; Flynn, JM; Guinn, D; Jaglowski, SM; Johnson, AJ; Jones, JA; Lehman, A; Maddocks, K; Woyach, JA; Yu, L, 2017) |
| "The therapy for chronic lymphocytic leukemia (CLL) is undergoing a major transformation." | ( Molica, S, 2017) |
| "Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy." | ( Bence-Bruckler, I; Coutre, S; Delage, R; Owen, CJ; Shustik, C; Toze, CL, 2017) |
| "Elderly/comorbid patients with chronic lymphocytic leukemia (CLL) require low-toxicity treatments." | ( Ando, K; Fujita, T; Hatake, K; Ogura, M; Takada, K; Taniwaki, M; Zhang, F, 2017) |
| "The established treatment algorithms for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are currently challenged by novel classes of drugs, with ibrutinib being one of the most effective." | ( Kalpadakis, C; Koulieris, E; Moschogiannis, M; Pangalis, GA; Rontogianni, D; Sachanas, S; Tsirkinidis, P; Yiakoumis, X, 2017) |
| "Patients with chronic lymphocytic leukemia (CLL) having a chromosomal loss on the short arm of chromosome 17 including the TP53 gene locus (17p deletion) and/or having mutations in TP53 have a short overall survival and, until recently, limited treatment options." | ( Edelmann, J; Gribben, JG, 2017) |
| "Patients with chronic lymphocytic leukemia with the 17p deletion have a poor prognosis and treatment options are limited." | ( Griffiths, CL; Olin, JL; Smith, MB, 2018) |
| "Richter syndrome (RS) is a rare event in chronic lymphocytic leukemia (CLL) that is influenced by biological factors and prior CLL treatments." | ( Albi, E; Ascani, S; Aureli, P; Baldoni, S; Del Papa, B; Di Ianni, M; Dorillo, E; Falzetti, F; Sportoletti, P, 2017) |
| "Discussion One patient with chronic lymphocytic leukemia/small lymphocytic lymphoma and one patient with mantle cell lymphoma developed laboratory and clinical tumor lysis syndrome following initiation of ibrutinib therapy." | ( Brown, JN; Hammond, JM; Titus-Rains, KS, 2018) |
| "The landscape of chronic lymphocytic leukemia (CLL) treatment has changed considerably since the first reported assessment of minimal residual disease (MRD) by flow cytometry in 1992." | ( Brander, D; Mato, A; Nabhan, C; Thompson, M, 2018) |
| "Here we show that treatment of chronic lymphocytic leukemia cells (CLL) with IT-901 effectively interrupts NF-κB transcriptional activity." | ( Allan, JN; Arruga, F; Deaglio, S; Furman, RR; Gaudino, F; Liou, HC; Moscvin, M; Ouk, S; Serra, S; Vaisitti, T; Vitale, N; Zakrzewski, JL, 2017) |
| "Elderly patients with chronic lymphocytic leukemia (CLL) or patients with comorbidities are often treated with chlorambucil (Chl) as front-line therapy despite relatively low response rates." | ( Autore, F; Efremov, DG; Innocenti, I; Laurenti, L; Morelli, F; Pasquale, R, 2017) |
| "His medical history was significant for chronic lymphatic leukemia, which had been stable without treatment, arterial hypertension, multiple squamous cell carcinomas of the scalp, and alcohol overuse." | ( Imhof, A; Klarer, A; Luginbuehl, M, 2017) |
| "Ibrutinib represents a revolution in chronic lymphocytic leukemia treatment scenario providing results never seen before and offering an effective therapy even in high-risk patients with really poor outcome after chemoimmunotherapy." | ( Cairoli, R; Deodato, M; Frustaci, AM; Mazzucchelli, M; Montillo, M; Tedeschi, A, 2018) |
| "Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted agents." | ( Bozic, I; Burger, JA; Cibulskis, C; Farooqui, MZH; Fein, J; Getz, G; Herman, SEM; Hoellenriegel, J; Landau, DA; Leshchiner, I; Liu, D; Livitz, D; Neuberg, DS; Ravichandran, S; Rosebrock, D; Sivina, M; Sun, C; Underbayev, C; Wiestner, A; Wu, CJ; Zhang, W; Zviran, A, 2017) |
| "We conducted a retrospective analysis of chronic lymphocytic leukemia patients treated with ibrutinib either commercially or on clinical trials." | ( Bachow, SH; Barr, P; Brander, DM; Cheson, BD; Claxton, D; Dorsey, C; Goy, A; Hill, B; Howlett, C; Isaac, K; Kennard, KH; Kiselev, P; Lamanna, N; Landsburg, D; Mato, AR; Nabhan, C; Nasta, SD; Pu, J; Schuster, SJ; Skarbnik, A; Svoboda, J; Thompson, MC; Timlin, C; Ujjani, CS; Winter, A; Zent, C, 2018) |
| "This strategy represents a new era of chronic lymphocytic leukemia therapy where chemotherapy is increasingly replaced by targeted agents and treatment duration is tailored to the patient's individual tumor load and response." | ( Bahlo, J; Böttcher, S; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kreuzer, KA; Langerbeins, P; Stilgenbauer, S; von Tresckow, J; Wendtner, CM, 2018) |
| "A retrospective analysis of 126 chronic lymphocytic leukemia patients treated with frontline FCR: 63 received second-line treatment (41 relapsed, nine refractory [SD/PD], 13 prior toxicity)." | ( Arad, A; Aviv, A; Bairey, O; Braester, A; Fineman, R; Goldschmidt, N; Greenbaum, U; Herishanu, Y; Joffe, E; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T, 2018) |
| "Prior to novel targeted agents for chronic lymphocytic leukemia (CLL), the best chemoimmunotherapy regimen in patients with non-del(11q) disease was unclear." | ( Appelbaum, FR; Byrd, JC; Chang, JE; Couban, S; Fehniger, TA; Godwin, JE; Halvorson, AE; Heerema, NA; Hoke, E; Larson, RA; Mandrekar, SJ; Robinson, S; Ruppert, AS; Smith, MR; Stone, RM; Tallman, MS; Thirman, MJ, 2018) |
| "Laboratory testing and treatments for chronic lymphocytic leukemia (CLL) have changed dramatically within the last decade." | ( Beebe-Dimmer, JL; Ruterbusch, JJ; Schiffer, CA; Seymour, EK, 2019) |
| "Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges." | ( Achille, A; Deng, S; Fonseca, R; Jones, SS; Maharaj, K; Pabon-Saldana, M; Pinilla-Ibarz, J; Powers, JJ; Quayle, SN; Sahakian, E; Sotomayor, EM; Villagra, A, 2018) |
| "A 75-year-old white man with B-cell chronic lymphocytic leukemia on ibrutinib therapy and without significant past ocular history presented 1 day after uncomplicated phacoemulsification with in-the-bag intraocular lens implantation with multiple, discrete, pigmented cords in the anterior chamber." | ( Hwang, CK; Kim, BJ; Kolomeyer, AM, 2018) |
| "The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years." | ( Jain, N, 2018) |
| "Although the therapy of chronic lymphocytic leukemia (CLL) has changed rapidly over the last 5 years, the key considerations in selecting a therapy for a previously treated patient with CLL continue to include the nature of the prior therapy and the duration of prior remission to that therapy, the prognostic features of the disease, and the health and comorbidities of the patient in question." | ( Brown, JR, 2018) |
| "It is approved for treatment of chronic lymphocytic leukemia and is being investigated for other hematological malignancies." | ( Agarwal, SK; Bueno, OF; Dave, N; Hu, B; Marbury, T; Menon, RM; Miles, D; Salem, AH, 2019) |
| "Here, we report a case of an elderly chronic lymphocytic leukemia patient who developed multiple inflamed lesions and lower limb cellulitis in 100 days after initiating ibrutinib therapy." | ( Albattah, A; Alhijji, I; Alokka, R; Elazzazy, S; Ghasoub, R; Nemir, A; Taha, R, 2020) |
| "A 68-year-old male patient with relapsed chronic lymphocytic leukemia was started on ibrutinib 420 mg orally daily following multiple lines of therapy." | ( Albattah, A; Alhijji, I; Alokka, R; Elazzazy, S; Ghasoub, R; Nemir, A; Taha, R, 2020) |
| "The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax)." | ( Bishop, R; Bloor, A; Boucher, R; Brock, K; Devereux, S; Fegan, C; Forconi, F; Fox, CP; Gribben, JG; Hillmen, P; MacDonald, D; McCaig, A; Munir, T; Muñoz-Vicente, S; Patten, PEM; Pettitt, A; Rawstron, AC; Schuh, A; Yates, FJ, 2019) |
| "Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) may benefit from salvage chemoimmunotherapy (CIT)." | ( Callander, NS; Claxton, DF; Frankfurt, O; Gross, G; Kay, NE; Kempin, S; Ketterling, RP; Mazza, JJ; Paietta, EM; Saltzman, JN; Srkalovic, G; Sun, Z; Tallman, MS, 2019) |
| "Patients with chronic lymphocytic leukemia and unmutated immunoglobulin heavy-chain variable region gene (IGHV) have inferior survival from time of treatment in clinical studies." | ( da Cunha-Bang, C; Egholm, GJ; Enggard, L; Frederiksen, H; Hjalgrim, H; Niemann, CU; Poulsen, CB; Rostgaard, K; Rotbain, EC; Zahedi, B, 2020) |
| "In patients with chronic lymphocytic leukemia (CLL) it is commonly used in combination with rituximab (BR protocol) both in the first-line as well as subsequent lines of therapy, and in clinical trials it is often combined with new targeted therapies." | ( Bramowicz-Jarosz, B; Długosz-Danecka, M; Graboś-Michalak, J; Hus, I; Kopacz, A; Krochmalczyk, D; Malenda, A; Piotrowska, M; Potoczek, S; Raźny, M; Seweryn, M; Soroka-Wojtaszko, M; Szymczyk, A; Wąsik-Szczepanek, E; Wichary, R; Wołowiec, D; Zawirska, D, 2019) |
| "A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of ibrutinib, a first-in-class oral inhibitor of Bruton tyrosine kinase (BTK), for the treatment of relapsed/refractory (R/R) and/or TP53 mutated patients with CLL." | ( Matutes, E; Molica, S; Polliack, A; Tam, C, 2020) |
| "After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data from two randomized registration trials with two real-world databases." | ( Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R, 2019) |
| "Progression of chronic lymphocytic leukemia (CLL) and resistance to therapy are affected by tumor microenvironmental factors." | ( Antonucci, L; Ghia, EM; Karin, M; Kipps, TJ; Rassenti, LZ; Sanchez-Lopez, E; Sharma, N; Sun, B; Xu, J, 2020) |
| "Therapy regimens for Chronic lymphocytic leukemia (CLL) commonly include chemotherapy and immunotherapy, which act through complement-mediated-cytotoxicity (CDC) and other mechanisms." | ( Aviv, A; Barhoum, M; Braester, A; Majdob, R; Michelis, R; Shehadeh, M; Shvidel, L; Stemer, G; Tadmor, T, 2020) |
| "Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib - a first-in-class inhibitor of BTK." | ( Brown, JR; Cohen, A; Eichhorst, BF; Hilger, J; Hillmen, P; Huang, J; Lamanna, N; O'Brien, SM; Qiu, L; Salmi, T; Tam, CS; Wu, K, 2020) |
| "Response of chronic lymphocytic leukemia (CLL) patients to classical chemoimmunotherapy that remains the main strategy in treatment of this disease is strikingly variable." | ( Gordiienko, I; Ivanivska, T; Shcherbina, V; Shlapatska, L; Sidorenko, S, 2020) |
| "Advances in the molecular biology of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and development of molecularly targeted therapies have resulted in treatment innovations." | ( Suzumiya, J; Takizawa, J, 2020) |
| "Ibrutinib is used for the treatment of chronic lymphocytic leukemia and other lymphoid malignancies." | ( Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020) |
| "In patients with recurrent chronic lymphocytic leukemia (CLL), treatment with targeted agents such as Bruton tyrosine kinase inhibitors and the Bcl-2 inhibitor venetoclax is rapidly replacing chemo-immunotherapy regimens." | ( Ferrajoli, A; Vitale, C, 2020) |
| "Patients were mainly treated for chronic lymphocytic leukemia." | ( Boutoille, D; Brochard, J; Guimard, T; Le Pape, P; Leterrier, M; Mahe, B; Mahe, J; Morio, F; Morrier, M; Raffi, F, 2020) |
| "We analyzed 33 chronic lymphocytic leukemia patients who underwent venetoclax RDE after prior BTKi treatment." | ( Awan, FT; Bhat, SA; Byrd, JC; Desmond, E; Dotson, EK; Ford, J; Huang, Y; Iarocci, S; Jones, JA; Koenig, KL; Lucas, MS; Moran, ME; Rogers, KA; Sheredy, S; Wiczer, TE; Woyach, JA, 2020) |
| "In the last decade, the treatment of chronic lymphocytic leukemia (CLL) has shifted away from chemoimmunotherapy toward targeted novel agents such as small molecule inhibitors and antibodies." | ( Opat, S; Salvaris, R, 2021) |
| "Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have limited treatment options." | ( Choi, I; Fukuhara, N; Humphrey, K; Ishikawa, T; Izutsu, K; Kato, K; Kim, SY; Maruyama, D; Nishimura, Y; Ogawa, N; Okubo, S; Salem, AH; Terui, Y; Yamamoto, K, 2021) |
| "An 86-year old female requiring chronic lymphocytic leukemia-directed therapy due to a rising absolute lymphocyte count and worsening, transfusion-dependent anemia with a past medical history of dementia and dysphagia, was initiated on ibrutinib." | ( Arnall, JR; DiSogra, KY; Janes, A; Moore, DC; Park, SI; Tran, T, 2021) |
| "Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment; therefore, more sensitive methods to evaluate residual CLL cells in patients are required." | ( Aoki, S; Uchiyama, T; Yokoyama, A, 2020) |
| "The treatment of chronic lymphocytic leukemia (CLL) embodies one of the great success stories in translational research, with the development of therapies aimed at disrupting crucial pathways that allow for the survival and proliferation of the malignant clone." | ( Barrientos, JC; Rhodes, JM, 2020) |
| "Recent developments in the management of chronic lymphocytic leukemia (CLL) have moved the standard of care away from chemoimmunotherapy to targeted agents such as oral kinase inhibitors or BCL-2 antagonists, alone or in combination with anti-CD20 antibodies." | ( Al-Sawaf, O; Fischer, K; Hallek, M, 2020) |
| "This study aims to describe chronic lymphocytic leukemia (CLL) epidemiology, treatment patterns and outcomes in a 2." | ( Afik, R; Chodick, G; Cohen, R; Herishanu, Y; Kan, I; Sail, K; Shalev, V; Weil, C, 2021) |
| "A 77-year-old man with underlying chronic lymphocytic leukemia (CLL) on ibrutinib treatment was admitted because of a superinfected mosquito bite on the left ear and multiple partially necrotic skin lesions disseminated all over the entire body five days after returning from a trip to Colombia." | ( Einwächter, H; Konukiewitz, B; Rothe, K; Schmid, RM; Schneider, J; Spinner, CD; Verbeek, M; Wiedemann, GM, 2021) |
| "In this series of 712 patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib outside clinical trials, baseline ECOG-PS and neutropenia resulted as the most accurate predictors of treatment feasibility and outcomes." | ( Baratè, C; Biagi, A; Borella, C; Cairoli, R; Cassin, R; Cavalloni, C; Chiarenza, A; Ciolli, S; Coscia, M; Del Poeta, G; Deodato, M; Di Raimondo, F; Fresa, A; Frustaci, AM; Greco, A; Ielo, C; Lapietra, G; Laurenti, L; Mauro, FR; Montillo, M; Morelli, F; Murru, R; Pelle, AC; Postorino, M; Reda, G; Rossi, V; Sportoletti, P; Tedeschi, A; Varettoni, M; Vitale, C; Zamprogna, G, 2021) |
| "The treatment landscape of chronic lymphocytic leukemia (CLL) has dramatically changed over the last few years with the introduction of novel targeted agents." | ( Gaballa, S; Pinilla-Ibarz, J, 2021) |
| "Both chronic lymphocytic leukemia (CLL) itself and the drugs used for its treatment, pose a risk for progressive multifocal leukoencephalopathy (PML)." | ( Akyar, I; Çetintepe, L; Çetintepe, T; Gediz, F; Koç, AM, 2022) |
| "Patients with chronic lymphocytic leukemia (CLL) have terminally differentiated T cells with an exhausted phenotype and experience low complete response rates after autologous CART therapy." | ( Chandrakasan, S; Chen, KZ; Coma, S; Edgar, CL; Fedanov, A; Flowers, CR; Funk, CR; Gupta, VA; Koff, JL; Pachter, JA; Raikar, SS; Ravindranathan, S; Shanmugam, M; Sharma, A; Spencer, HT; Waller, A; Waller, EK; Wang, S; Zoine, JT, 2022) |
| "Blood was obtained from patients with chronic lymphocytic leukemia, mantle-cell lymphoma and Waldenström macroglobulinemia with and without ibrutinib treatment and perfused through a microfluidic channel with(out) 60% stenosis over Horm type I collagen or human atherosclerotic plaque homogenate." | ( Claushuis, TAM; Cosemans, JMEM; D'Italia, G; Karel, MFA; Kuijpers, MJE; Lemmens, TP; Tullemans, BME, 2022) |
| "Among patients with chronic lymphocytic leukemia (CLL) with deletion 17p (del[17p]), evidence from clinical trials for the effectiveness of single-agent ibrutinib as first-line therapy is limited." | ( Azmi, S; Hedrick, E; Huang, J; Mato, AR; Sharman, JP; Stern, JC; Tang, B; Yang, K; Zhang, X, 2022) |
| "Patients with chronic lymphocytic leukemia (CLL) relapsing on ibrutinib are often treated with the Bcl-2 inhibitor venetoclax." | ( Ferrarini, I; Gandini, F; Rigo, A; Zapparoli, E, 2022) |
| "Successes with anti-CD20 antibodies in chronic lymphocytic leukemia (CLL) and enhanced activity of Fc-engineered vs unmodified antibody therapy suggest a potentially impactful role for natural killer (NK) cells and other innate immune cells in controlling this disease." | ( Bhat, S; Byrd, JC; Kittai, AS; Lance, JR; Lee, DA; Mo, X; Muthusamy, N; Ravikrishnan, J; Rogers, KA; Sampath, D; Sharpe, C; Vasu, S; Woyach, JA; Yano, M; Zapolnik, K, 2022) |
| "Certain genetic features in chronic lymphocytic leukemia (CLL) are associated with inferior outcomes after chemoimmunotherapy (CIT)." | ( Deering, KL; Harshaw, Q; Huang, Q; Leslie, LA, 2022) |
| "Treatment of chronic lymphocytic leukemia (CLL) has been transformed in the past two decades." | ( Cheah, CY; Hsieh, WS; Kuss, B; Nagarajan, C, 2022) |
| "Standard treatment for chronic lymphocytic leukemia (CLL) has experienced a dramatic change over the last few years." | ( Blachnio, K; Grygalewicz, B; Kawiak, J; Pienkowska-Grela, B; Rygier, J; Rymkiewicz, G; Woroniecka, R, 2022) |
| "Patient was known for remote history of chronic lymphocytic leukemia (CLL), previously treated." | ( Alabed, YZ, 2023) |
| "Clinical outcomes in chronic lymphocytic leukemia (CLL) have improved with targeted therapy, including Bruton tyrosine kinase inhibitors such as acalabrutinib." | ( Gaitonde, P; Genestier, V; Genovez, V; Liljas, B; Munir, T; Ryan, K, 2023) |
| "The treatment of chronic lymphocytic leukemia (CLL) currently relies on the use of chemo-immunotherapy, Bruton's tyrosine kinase inhibitors, or BCL2 inhibitors alone or combined with an anti-CD20 monoclonal antibody." | ( Botta, C; Camarda, GM; Gentile, M; Gigliotta, E; Mancuso, S; Pirrera, A; Rizzuto, A; Roppolo, A; Rotolo, C; Siragusa, S; Spoto, C; Vullo, C, 2023) |
| "The treatment landscape for chronic lymphocytic leukemia (CLL) continues to undergo considerable evolution." | ( Anderson, MA; Bennett, R; Seymour, JF, 2023) |
| "Patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib are at risk of developing cardiovascular side effects (CVSE)." | ( Avalos, B; Copelan, E; Ghosh, N; Hamadeh, IS; Hamilton, A; He, J; Hu, B; Jacobs, R; Moyo, TK; Park, S; Patel, JN; Soni, A; Steuerwald, N; Zeng, H, 2023) |